Citius Pharmaceuticals (CTXR)

• Market cap: $20.4M
• 1 day: -2.26%
• 5 days: 3.41%
• 1 month: 1.19%
• 3 months: -21.55%
• 6 months: -24.17%
• Year to date: 7.31%
• 1 year: -43.48%
• 5 years: -98.09%
• 10 years: -98.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Employees: 23